Does Vitamin C Increase the Body Heat Generated By The Nervous System?

NCT ID: NCT07341308

Last Updated: 2026-01-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-17

Study Completion Date

2026-12-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goals of this clinical trial are to determine whether or not vitamin C is able to: (1) increase the body heat generated by the sympathetic nervous system; and, (2) increase circulating vitamin D concentration during sympathetic nervous system stimulation in adult humans aged 18-40 years who meet the criteria for overweight based on body mass index. The main question it aims to answer are:

1. By how much does body temperature increase during stimulation of beta-adrenergic receptors when vitamin C is given.
2. By how much does circulating vitamin D concentration increase during stimulation of beta-adrenergic receptors when vitamin C is given.

Participants will will be asked to:

* undergo measures of body temperature
* have blood sampled on two separate occasions: once during stimulation of beta adrenergic receptors, and once during stimulation of beta-adrenergic receptors while also been given vitamin C.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants will be required to visit the lab twice. During each visit, beta-adrenergic receptors will be stimulated with isoproterenol. The two visits are identical in every way with one exception: during one visit the isoproterenol will be delivered with saline only, and during the other visit the isoproterenol will be delivered with saline and vitamin C. The order of the visits will be randomized. Body temperature will be measured with a thermometer and a thermal camera. venous blood will be sampled and circulating vitamin D concentration will be quantified.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolism Changes Vitamin D

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Response to beta-adrenergic stimulation without vitamin C

Isoproterenol will be infused with saline only

Group Type NO_INTERVENTION

No interventions assigned to this group

Adding vitamin C to beta-adrenergic receptor stilmulation

Isoproterenol will be infused with vitamin C

Group Type EXPERIMENTAL

Vitamin C

Intervention Type OTHER

Vitamin C will be co-infused with isoproterenol

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vitamin C

Vitamin C will be co-infused with isoproterenol

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-40 years (inclusive)
* Body mass index greater than or equal to 25 kg/m2 and less than 30 kg/m2
* Weight stable (no change in body mass greater than 5 Lbs. within the previous 6 months.
* Willing to abstain from caffeine and alcohol for 24-hours prior to two different study visits
* Competency in English as assessed by comprehension of the Informed Consent. This is study involves invasive procedures and infusion of a systemic vasoactive agent (isoproterenol); for safety reasons, the ability for clear and rapid communication will be necessary between the research participants and the investigators.

Exclusion Criteria

* History of autonomic, cardio-pulmonary, and/or metabolic disease (including heart failure, hypertension, arrhythmia, vascular disease, and/or diabetes)
* Pregnancy or breast feeding
* Habitual use of tobacco/nicotine products or recreational drugs (2 or more uses within the previous month)
* History of a "sulfite allergy" as it is a relative contraindication to isoproteronol use.
* Has ingested vitamin supplements and/or antioxidant supplements during the previous 4-weeks (e.g. Vitamin C, Vitamin E, Multi-vitamins, etc.)
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Colorado State University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christopher Bell, PhD

Role: PRINCIPAL_INVESTIGATOR

Colorado State University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Colorado State University

Fort Collins, Colorado, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Christopher Bell, PhD

Role: CONTACT

9704917522

Taylor Ewell, M.S.

Role: CONTACT

9704913495

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Christopher Bell, PhD

Role: primary

9704917522

Taylor Ewell, MS

Role: backup

9704913495

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

6115

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Nutrient-Fortified Beverage Study
NCT02103192 COMPLETED NA